Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

806 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
De Angelis F, Cameron JR, Eshaghi A, Parker R, Connick P, Stutters J, Plantone D, Doshi A, John N, Williams T, Calvi A, MacManus D, Barkhof F, Chandran S, Weir CJ, Toosy A, Chataway J; MS-SMART trial investigators. De Angelis F, et al. J Neurol Neurosurg Psychiatry. 2024 Dec 18:jnnp-2024-334801. doi: 10.1136/jnnp-2024-334801. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39694820
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Giovannoni G, et al. Mult Scler. 2024 Dec 17:13524585241302170. doi: 10.1177/13524585241302170. Online ahead of print. Mult Scler. 2024. PMID: 39690897
Effects of cladribine on intrathecal and peripheral B and plasma cells.
Allen-Philbey K, Stephenson S, Doody G, MacDougall A, Aboulwafaali M, Ammoscato F, Andrews M, Gnanapavan S, Giovannoni G, Grigoriadou S, Hickey A, Holden DW, Lock H, Papachatzaki M, Redha I, Baker D, Tooze R, Schmierer K. Allen-Philbey K, et al. Among authors: giovannoni g. Clin Exp Immunol. 2024 Dec 12:uxae116. doi: 10.1093/cei/uxae116. Online ahead of print. Clin Exp Immunol. 2024. PMID: 39663507
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells.
Ammoscato F, Wafa M, Skonieczna J, Bestwick J, Monero R, Andrews M, De Trane S, Holden D, Adams A, Bianchi L, Turner B, Marta M, Schmierer K, Baker D, Giovannoni G, Gnanapavan S. Ammoscato F, et al. Among authors: giovannoni g. Clin Immunol. 2024 Dec;269:110380. doi: 10.1016/j.clim.2024.110380. Epub 2024 Oct 18. Clin Immunol. 2024. PMID: 39428028 Free article.
FROM BENCH TO BEDSIDE: A SNAIL IN TREACLE?
Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Yeh A. Hawkes CH, et al. Among authors: giovannoni g. Mult Scler Relat Disord. 2024 Nov;91:105916. doi: 10.1016/j.msard.2024.105916. Epub 2024 Oct 1. Mult Scler Relat Disord. 2024. PMID: 39406046 No abstract available.
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
Derfuss T, Bermel R, Lin CJ, Hauser SL, Kappos L, Vollmer T, Comi G, Giovannoni G, Hartung HP, Weber MS, Wang J, Jessop N, Chognot C, Craveiro L, Bar-Or A. Derfuss T, et al. Among authors: giovannoni g. Ther Adv Neurol Disord. 2024 Oct 8;17:17562864241277736. doi: 10.1177/17562864241277736. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39399100 Free PMC article.
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Wiendl H, Li K, Dsilva L, Toukam M, Ferber K, Sohn J, Engelman H, Lasky T. Foley JF, et al. Among authors: giovannoni g. Neurol Neuroimmunol Neuroinflamm. 2024 Dec;11(6):e200321. doi: 10.1212/NXI.0000000000200321. Epub 2024 Oct 11. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39393045 Free PMC article. Clinical Trial.
806 results